Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Eureka Therapeutics

- PMLiVE

Sanofi’s Rezurock fast-tracked by NHS for rare chronic graft versus host disease

Around 400 stem cell or bone marrow transplant patients will develop the condition each year in England

- PMLiVE

Sanofi presents positive results for rilzabrutinib in chronic spontaneous urticaria

Phase 3 development of the treatment is expected to commence later this year

- PMLiVE

Janssen’s Carvykti recommended by CHMP for earlier multiple myeloma treatment

The blood cancer affects approximately 160,000 people worldwide

- PMLiVE

Sanofi’s investigational frexalimab shows promise in relapsing forms of MS

Results from a mid-stage of the candidate were recently published in the NEJM

- PMLiVE

Sanofi presents positive results for Pompe disease enzyme replacement therapy

The rare genetic disorder is estimated to affect around one in every 40,000 people in the UK

- PMLiVE

GSK shares positive results for Blenrep combination in head-to-head multiple myeloma study

Approximately 176,000 new cases of multiple myeloma are diagnosed globally each year

regeneron headquarters

Regeneron to acquire 2seventy’s investigational cell therapy pipeline

An estimated 150 2seventy employees will join Regeneron’s new research and development unit

- PMLiVE

BMS announces CHMP recommendation for multiple myeloma therapy Abecma

More than 50,000 cases of the blood cancer are diagnosed in Europe every year

- PMLiVE

Sanofi/Regeneron’s Dupixent approved by FDA for younger eosinophilic oesophagitis patients

Around 21,000 children aged under 12 years in the US are being treated for the inflammatory disease

- PMLiVE

Sanofi expands rare disease pipeline with $2.2bn Inhibrx acquisition

The deal includes a mid-stage candidate for alpha-1 antitrypsin deficiency

- PMLiVE

Sanofi/Regeneron’s Dupixent gets US label update for atopic dermatitis

Dupixent’s label now includes data supporting its use in hand and foot atopic dermatitis

- PMLiVE

AstraZeneca/Sanofi’s RSV treatment shown to reduce hospitalisations in infants

Beyfortus showed an over 80% reduction in hospitalisations associated with the virus

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links